Table of Contents
Overview
New York, NY – July 22, 2025 – The Endocrine Testing Market Size is expected to be worth around USD 6.1 billion by 2033 from USD 2.7 billion in 2023, growing at a CAGR of 8.5% during the forecast period 2024 to 2033.
The global endocrine testing market is experiencing steady growth, driven by the increasing prevalence of hormonal imbalances, rising awareness about endocrine disorders, and continuous advancements in diagnostic technologies. Endocrine testing plays a critical role in diagnosing and monitoring disorders related to the endocrine glands, such as thyroid, pituitary, adrenal, and reproductive hormones.
The market growth is supported by the increasing incidence of conditions such as diabetes, thyroid dysfunction, infertility, and metabolic disorders. According to the World Health Organization (WHO), over 422 million people worldwide suffer from diabetes, highlighting the need for early and accurate endocrine testing.
Technological advancements, including the development of highly sensitive immunoassays, mass spectrometry-based tests, and automation of laboratory workflows, have significantly improved diagnostic accuracy and turnaround time. Additionally, the growing demand for point-of-care testing and home-based diagnostic kits has expanded access to hormone testing services.
Hospitals, diagnostic laboratories, and research institutions are the primary end-users of endocrine testing services, with North America leading the market due to its advanced healthcare infrastructure and high disease awareness.
As the global focus on preventive healthcare intensifies, the endocrine testing market is expected to witness sustained growth, supported by increasing healthcare spending, government screening initiatives, and expanding applications in personalized medicine.
Key Takeaways
- In 2023, the market for Endocrine Testing generated a revenue of USD 2.7 billion, with a CAGR of 8.5%, and is expected to reach USD 6.1 billion by the year 2033.
- The test type segment is divided into progesterone test, testosterone test, thyroid stimulating hormone test, human chorionic gonadotropin hormone test, cortisol test, insulin test, and others, with thyroid stimulating hormone test taking the lead in 2023 with a market share of 26.7%.
- Considering technology, the market is divided into immunoassay, mass spectroscopy, chromatography, and nucleic acid-based. Among these, mass spectroscopy held a significant share of 38.2%.
- Furthermore, concerning the end-user segment, the market is segregated into hospitals, commercial laboratories, and others. The hospital sector stands out as the dominant player, holding the largest revenue share of 53.8% in the Endocrine Testing market.
- North America led the market by securing a market share of 40.6% in 2023.
Segmentation Analysis
- Test Type Analysis: In 2023, the thyroid stimulating hormone (TSH) test segment dominated the market with a 26.7% share, driven by the rising incidence of thyroid disorders such as hypothyroidism and hyperthyroidism. Growing awareness of thyroid health and an aging population are key contributors. TSH tests are frequently used in routine checkups due to their reliability and improved accuracy. Continued emphasis on early detection and better clinical outcomes is expected to support the segment’s growth.
- Technology Analysis: Mass spectrometry accounted for 38.2% of the market in 2023, supported by its superior precision in detecting low-concentration hormones like cortisol and testosterone. Its high sensitivity and ability to generate detailed molecular profiles make it a preferred choice for clinical and research use. Technological advancements, including compact, faster instruments, are expected to increase its adoption further. As the demand for accurate hormone analysis rises, mass spectrometry is likely to maintain a leading position in endocrine diagnostics.
- End-user Analysis: Hospitals held the largest revenue share at 53.8% in 2023, owing to their advanced diagnostic infrastructure and skilled personnel. With increasing cases of endocrine conditions such as diabetes and thyroid disorders, hospitals remain the primary destination for complex testing and treatment. Their ability to manage a high patient load and deliver comprehensive care supports sustained demand. As public health awareness and access to services improve, hospitals are expected to see continued growth in endocrine testing volume.
Market Segments
By Test Type
- Progesterone Test
- Testosterone Test
- Thyroid Stimulating Hormone Test
- Human Chorionic Gonadotropin Hormone Test
- Cortisol Test
- Insulin Test
- Others
By Technology
- Immunoassay
- Mass Spectroscopy
- Chromatography
- Nucleic Acid Based
By End-user
- Hospitals
- Commercial Laboratories
- Others
Regional Analysis
North America emerged as the leading region in the global endocrine testing market in 2023, accounting for a revenue share of 40.6%. This dominance is attributed to the growing prevalence of endocrine disorders, particularly thyroid cancer, and heightened public awareness.
According to Science Direct, an estimated 43,800 new thyroid cancer cases were expected in the U.S. in 2022, including 11,860 among men and 31,940 among women, with 2,230 related deaths. This high disease burden has intensified the demand for thyroid function tests, emphasizing the need for early diagnosis and monitoring. Moreover, the availability of advanced diagnostic technologies, routine screening programs, and government initiatives aimed at expanding healthcare access have significantly contributed to market growth across the region.
Asia Pacific is projected to witness the fastest compound annual growth rate (CAGR) over the forecast period. The rising prevalence of diabetes, thyroid disorders, and other hormonal imbalances is a key driver for market expansion. Countries such as China, Japan, and India are experiencing increased adoption of modern diagnostic tools, supported by improvements in healthcare infrastructure.
Initiatives launched in October 2022 to strengthen diagnostic capabilities across the region are expected to boost testing rates. Additionally, growing awareness regarding the importance of early detection, along with increased healthcare investments and supportive government policies, positions Asia Pacific as a major growth region in endocrine diagnostics.
Emerging Trends
- Point of care hormone assays have been adopted to deliver rapid results outside of central labs. Lateral flow devices for hormones now cost less than £1 per test and provide results in under five minutes. Their simplicity and low cost have driven a shift toward on site screening in clinics and field settings.
- Standardization of key hormone tests has been advanced through U.S. Centers for Disease Control and Prevention efforts. VitaminD assays certified under the CDC Clinical Standardization Program have been shown to be well calibrated across laboratories, ensuring consistency of patient results nationwide.
- Population level hormone monitoring has been expanded via the CDC Environmental Health Tracking network. Routine measurement of hormone related biomarkers in communities is now conducted to detect shifts in exposure to endocrine active agents and to guide public health responses.
- Broadened chemical screening mandates have been implemented by the U.S. Environmental Protection Agency (EPA). Through the Endocrine Disruptor Screening Program, chemicals in commerce are systematically evaluated for potential endocrine disrupting effects, supporting regulation and risk mitigation.
Use Cases
- Diabetes care and monitoring relies on regular endocrine panels. In 2021, among U.S. adults with diagnosed diabetes, 87.9% received all three recommended “ABC” tests (A1C, blood pressure, cholesterol) in the past year. Specifically, 94.2% had an A1C test, 96.8% had blood pressure checked, and 93.0% had cholesterol measured.
- Thyroid disorder diagnosis and management depend heavily on laboratory assays. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) tests rank as the most frequently ordered endocrine assays in U.S. clinical laboratories, reflecting the high prevalence of thyroid disease and the tests’ sensitivity in detecting dysfunction.
- Clinical research interventions are using endocrine biomonitoring to reduce harmful exposures. In a recent trial (NCT06450951), 600 reproductive‑age adults were randomized to receive personalized urine testing for endocrine disrupting chemicals plus educational support. The study aims to quantify changes in urinary metabolites and behavioral readiness to reduce exposures.
- Public health surveillance incorporates endocrine testing for environmental health. Hormone level tracking in populations is used to identify emerging risks from environmental chemicals (e.g., pesticides, industrial agents) and to inform targeted interventions in affected communities.
Conclusion
The global endocrine testing market is poised for continued growth, driven by rising hormonal disorders, technological innovation, and increasing public health initiatives. With strong contributions from thyroid and diabetes diagnostics, supported by advancements such as mass spectrometry and point-of-care testing, the market is becoming more accessible and accurate.
North America maintains market leadership, while Asia Pacific is set to grow rapidly due to expanding healthcare infrastructure. Ongoing regulatory support, standardization efforts, and the integration of endocrine testing in population health monitoring underscore the market’s essential role in preventive care, early diagnosis, and personalized treatment strategies worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
